Frazier Life Sciences Closes $138M IPO

As announced in December, the transaction would deliver approximately $512 million in cash to Eve. The pro forma equity value of the combined company was cited as $2.9 billion, assuming no SPAC share redemptions.

Current Clarus stakeholders will invest an additional $25 million in the therapeutics company.

The new SPAC will focus on companies that provide technological services to the financial services industry and are domiciled in Israel, carry out all or a substantial portion of their activities in Israel, or that have some other significant Israeli connection.